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Background: The fourth edition of the ‘’WHO Classification of Head and Neck Tumours’’ was published in Janu-
ary 2017 and includes a classification of odontogenic tumours. This review aims to examine the changes made in 
this new classification in comparison with the previous classification of 2005.
Material and Methods: An electronic search was conducted in the PubMed, Scopus and Cochrane databases with 
the keywords “odontogenic tumor”, “WHO classification” and “update”. Studies published from January 2009 to 
April 2019 with a high level of scientific evidence were included, but studies not published in English, epidemio-
logical studies and studies with a low level of evidence were excluded.
Results: The initial search found 457 articles and after eliminating duplicates, 8 studies were selected for full-text 
assessment. After excluding 3 epidemiological studies, 5 articles were finally included. These studies were strati-
fied by their level of scientific evidence using SORT criteria (Strength of Recommendation Taxonomy).
Conclusions: The new odontogenic tumour list has been simplified with the objective of improving its role as an 
international guide for diagnosis. Some changes have been possible thanks to the application of immunohisto-
chemistry and molecular genetic techniques that allow better characterization of certain tumours. Further clinico-
pathological and molecular studies are needed so that this new classification can be consolidated and/or amended.
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the new 2017 WHO odontogenic tumour classification 
(1) compared with the previous classification published 
in 2005 (4).
Material and Methods
A bibliographical search was performed in the Co-
chrane, Scopus and PubMed-MEDLINE databases 
using the search terms “odontogenic tumour”, “WHO 
classification” and “update”. Search terms were com-
bined using the Boolean operator “AND” with the aim 
of obtaining different articles that include two or more 
of the terms used for the search.
We included all studies published between January 
2009 and April 2019 that were written in English and 
had level 1 or 2 scientific evidence according to SORT 
criteria (Strength of Recommendation Taxonomy) (8). 
Studies were excluded if they were not written in Eng-
lish, had an epidemiological aim or had level 3 scientific 
evidence according to SORT criteria (8).
Results
We obtained 457 articles from the initial search in the 
different databases, and 420 after removing duplicates, 
corresponding to 214 studies from PubMed-MEDLINE, 
243 from Scopus and none from Cochrane. 371 studies 
were then discarded after reading the title and the 49 re-
maining articles were screened by reading the abstract. 
Of these, 41 were discarded because they only concerned 
odontogenic cysts or odontogenic tumour treatment or 
did not contribute any relevant information relating to 
the new classification. From the remaining 8 articles as-
sessed for full-text eligibility, 3 studies were excluded 
because they were epidemiological studies and did not 
meet the inclusion criteria. Finally, 5 studies were in-
cluded for this review: three systematic reviews, one 
retrospective study and a review. Fig. 1 shows the flow-
chart of the review process under PRISMA criteria (9).
The studies were stratified according to their scientific 
evidence level using SORT criteria (8), resulting in 3 ar-
ticles with level 1 evidence and 2 with level 2 evidence.
First of all, it is recognized that the malignant tumour 
list presented in the new classification has been sim-
plified compared with the previous one. The list of tu-
mours is reduced from 12 entities in 2005 to 7 entities in 
2017 (Table 1). As a consequence of this simplification, 
there is only one type of ameloblastic carcinoma and 
one type of primary intraosseous carcinoma, as tumour 
entities with adjectives such as secondary, not differ-
entiated, etc. have been deleted. In addition, this new 
edition proposes the acknowledgment of only one type 
of odontogenic sarcoma (1).
The new classification also acknowledges one new type 
of malignant tumour, sclerosing odontogenic carci-
noma, based on previous publications concerning this 
tumour (10-12).
Introduction
Odontogenic tumours are defined as a neoplasms exclu-
sively of the maxillary bones and oral mucosa, which 
derive from odontogenic epithelial tissue, odontogenic 
ectomesenchymal tissue or both (1). Odontogenic tu-
mours represent less than 1% of all head and neck tu-
mours. Benign tumours are more frequent and can 
occasionally show aggressive local growth and have a 
high recurrence rate (1).
In 1971, the World Health Organization (WHO) pub-
lished the first odontogenic tumour classification with 
the aim of structuring and clarifying this type of pa-
thology (2). This classification was revised in 1992 (3) 
and updated in 2005 (4). In January 2017, the ninth vol-
ume of the fourth edition of the WHO series was pub-
lished, entitled ‘’WHO Classification of Head and Neck 
Tumours’’, following the consensus of various interna-
tional experts. This monograph details odontogenic tu-
mours alongside other tumours that affect the head and 
neck region.
The 2005 classification (4) needed a revision because 
some odontogenic tumour processes were explained 
unclearly, with confusing terminology and debatable 
scientific evidence, which limited its use as a univer-
sal guide for diagnosis and management of odonto-
genic tumours (5). A significant change made in the 
2005 classification (4) was the removal of the chapter 
on odontogenic cysts and the reclassification of some 
cystic lesions as keratocystic odontogenic tumours or 
calcifying cystic odontogenic tumours.
The main aim of the 2017 classification (1) has been to 
simplify the odontogenic tumour list proposed in 2005 
(4) and to provide scientific evidence for each entity in-
cluded in the new classification. In addition, in this edi-
tion, odontogenic cysts have been reincorporated, and 
these have been significantly updated since the 1992 
classification (6,7).
The new odontogenic tumour classification distin-
guishes between benign and malignant tumours, as did 
the previous version (1). In 2005 (4), benign tumours 
were classified in three categories based on their origin: 
odontogenic epithelium with mature, fibrous stroma 
without odontogenic ectomesenchyme; odontogenic 
epithelium with odontogenic ectomesenchyme, with or 
without hard tissue formation; and mesenchyme and/or 
odontogenic ectomesenchyme with or without odonto-
genic epithelium. Despite the histological accuracy of 
these groups, the 2017 classification (1) has simplified 
them: epithelial odontogenic tumours, mixed epithelial 
and mesenchymal odontogenic tumours, and mesen-
chymal (ectomesenchymal) tumours.
Regarding malignant odontogenic tumours, both clas-
sifications maintain the distinction between carcinomas 
and sarcomas (1,4).
This review aims to analyse the main changes made in 
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Fig. 1: Flow-chart of the review process modified from the PRISMA statement.
2005 classification 2017 classification
Odontogenic carcinomas Odontogenic carcinomas
Metastasizing (malignant) ameloblastoma Ameloblastic carcinoma
Ameloblastic carcinoma – primary type Primary intraosseous carcinoma, NOS
Ameloblastic carcinoma – secondary type (dedifferentiated), intraosseous Sclerosing odontogenic carcinoma
Primary intraosseous squamous cell carcinoma – solid type Clear cell odontogenic carcinoma
Primary intraosseous squamous cell carcinoma derived from keratocystic 
odontogenic tumour
Ghost cell odontogenic carcinoma
Primary intraosseous squamous cell carcinoma derived from odontogenic cysts
Clear cell odontogenic carcinoma
Ghost cell odontogenic carcinoma
Odontogenic carcinosarcoma




Table. 1: Comparison of malignant odontogenic tumours.
Regarding benign tumours, the 2005 classification has 
likewise been simplified with the disappearance of 
some entities (Table 2). There is also the addition of a 
new benign neoplasm, the primordial odontogenic tu-
mour, described and categorized in 2014 (13).
With odontogenic cysts incorporated into the new 2017 
WHO text (1), keratocystic odontogenic tumour and 
calcifying epithelial odontogenic tumour are once again 
considered as cystic entities, respectively odontogenic 
keratocyst and calcifying epithelial cyst.
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Discussion
- Malignant odontogenic tumours
Ameloblastic carcinoma was divided in the 2005 clas-
sification into three categories: primary, secondary 
intraosseous and secondary peripheral. In this new 
classification, it was decided to delete these categories 
because they had very similar morphology and clinical 
behaviour (6). This malignant tumour shares the BRAF 
V600E mutation with its benign counterpart, amelo-
blastoma. When diagnosing this tumour, sex-determin-
ing region Y-related high mobility group box 2 (SOX2) 
and high proliferation index (Ki-67) are necessary to 
distinguish it from ameloblastoma (14,15).
Primary intraosseous carcinoma is a single entity in 
this edition (1), unlike in the previous classification (4) 
where it was divided into three categories based on its 
histogenesis. 
Sclerosing odontogenic carcinoma is a new malignant 
tumour included in this classification (1) after being de-
scribed by Koutlas et al. in 2008 (10) and with more 
than 10 cases reported (10-12). It is a primary intraos-
seous carcinoma with an epithelial component with 
low-level atypia and pleomorphism within sclerotic 
connective stroma that can infiltrate muscle and nerve 
structures (1). It has not yet been clarified whether it 
constitutes a specific entity or a particular histomorpho-
logical pattern, and more extensive tumoral character-
ization is necessary to justify this tumour as a unique 
entity (6,15).
There have been no major changes to clear cell odonto-
genic carcinoma in this new classification, beyond im-
munohistochemistry and genetic characterization (1). 
Proliferation index (Ki-67) greater than 20% and posi-
tive MMP-9 (metalloproteinase 9) differentiate it from 
other entities that are morphologically similar (15,16). 
80% of these carcinomas also show rearrangements in 
the EWSR1-ATF genes, although these rearrangements 
also appear in salivary gland hyalinizing clear cell car-
cinoma and other clear cell neoplasms (17).
A new malignant tumour entity, odontogenic carcinoma 
with dentinoid, was described for the first time in 2014 
(18). Nevertheless, it was decided not to include this in 
the 2017 classification (1) because it was felt that there 
was not enough scientific evidence and that more time 
2005 classification 2017 classification
Odontogenic epithelium with mature, fibrous 
stroma without odontogenic ectomesenchyme Epithelial origin
Ameloblastoma, solid/multicystic Ameloblastoma, conventional
Ameloblastoma, extraosseous/peripheral Ameloblastoma, unicystic
Ameloblastoma, desmoplastic Ameloblastoma, extraosseous/peripheral 
Ameloblastoma, unicystic Metastasizing ameloblastoma
Squamous odontogenic tumour Squamous odontogenic tumour
Calcifying epithelial odontogenic tumour Calcifying epithelial odontogenic tumour
Adenomatoid odontogenic tumour Adenomatoid odontogenic tumour
Keratocystic odontogenic tumour
Odontogenic epithelium with odontogenic 




Ameloblastic fibroma Ameloblastic fibroma
Ameloblastic fibro-dentinoma Primordial odontogenic tumour
Ameloblastic fibro-odontoma Odontoma
Odontoma       Complex
      Complex       Compound
      Compound Dentinogenic ghost cell tumour
Odontoameloblastoma
Calcifying cystic odontogenic tumour
Dentinogenic ghost cell tumour
Mesenchyme and/or odontogenic ectomesen-
chyme with or without odontogenic epithelium Mesenchymal origin
Odontogenic fibroma Odontogenic fibroma
Odontogenic myxoma/myxofibroma Odontogenic myxoma/myxofibroma
Cementoblastoma Cementoblastoma
Cemento-ossifying fibroma
Table. 2: Comparison of benign odontogenic tumours.
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was needed to allow for additional new cases to be pub-
lished. This carcinoma is being discussed in relation to 
clear cell odontogenic carcinoma, which can show den-
tinoid in 7% of cases (6).
Odontogenic carcinosarcoma is an entity that was first 
described in the 1992 classification (3) and was deleted 
in the 2005 edition (4) because it had insufficient char-
acterization. After new cases were published, it was 
decided to reinclude this tumour in the 2017 classifica-
tion (19).
Regarding odontogenic sarcomas, in the previous edi-
tion (4) they were classified as ameloblastic fibrosarco-
ma, ameloblastic fibrodentinosarcoma or ameloblastic 
fibro-odontosarcoma. This classification was based on 
the presence of different hard dental tissue types and 
quantities (4). It has been stated that the most common 
type is ameloblastic fibrosarcoma (6) but the authors of 
the new classification consider that there is not enough 
scientific evidence to subclassify these odontogenic 
sarcomas (1). This simplification is not universally 
agreed and controversies may develop when new cases 
are published.
- Benign odontogenic tumours
a) Epithelial origin
There have been changes to the terminology and clas-
sification of ameloblastomas based on new discoveries 
about the genetic profile of this tumour (1). In the previ-
ous edition (4), ameloblastomas could be classified as 
solid / multicystic, peripheral / extraosseous, desmo-
plastic or unicystic. In this new edition, it was decided 
to delete the ‘‘solid / multicystic’’ adjective because it 
had little biological value and could lead to confusion 
with ‘’unicystic’’ ameloblastoma (6). However, Kenne-
dy (7) points out that pathologists continue to use these 
adjectives to differentiate conventional ameloblastoma 
(solid) from unicystic and other variants. In this edi-
tion, desmoplastic ameloblastoma is reclassified as a 
histopathological variant because despite its particular 
radiographic and clinical features, it behaves like any 
other ameloblastoma (6). Between the two classifica-
tions, various genetic mutations have been discovered 
in ameloblastomas. In 90% of these tumours, mutations 
in the MAPK pathway are found, with BRAF V600E 
being the most common mutation, whilst outside the 
MAPK pathway SMO mutation is the most frequently 
referenced (20-22).
Regarding unicystic ameloblastoma, there are cur-
rently three histopathological types: luminal, intralu-
minal and mural. The mural variant is controversial 
since it is considered to be more of a conventional 
ameloblastoma with cystic degeneration rather than a 
true unicystic ameloblastoma (6). As in conventional 
ameloblastoma, BRAF V600E mutations have been 
detected (23).
Metastasizing ameloblastoma is an odontogenic tumour 
that was classified in 2005 (4) as a malignant tumour. In 
this new edition (1), it has been decided to classify it as 
a benign tumour due to the benign histologic appear-
ance of both primary tumour and metastases. The most 
frequent metastases are in the lungs, followed by lymph 
nodes and bone (1,24).
In aggressive relapsing and/or metastatic ameloblas-
toma cases, apart from surgery, anti-BRAF biotherapy 
can be used. These are tyrosine kinase inhibitors (ve-
murafenib or dabrafenib + trametinib) (25,26).
There have been no major changes to squamous odonto-
genic tumour, calcifying epithelial odontogenic tumour 
or adenomatoid odontogenic tumour (1).
In 2005 (4), odontogenic cysts were not included in the 
classification and odontogenic keratocyst was listed as 
“keratocystic odontogenic tumour” inside the epitheli-
al-origin benign tumours category. In 2017 (1), with the 
reincorporation of odontogenic cysts, it has been reclas-
sified again as odontogenic keratocyst.
b) Epithelial-mesenchymal origin
Odontoameloblastoma, which has ameloblastic prolif-
eration and dental tissue formation, was added to this 
group in the 2005 classification (4). In the 2017 classifi-
cation (1), it was considered that this neoplasm does not 
constitute a unique entity because there is not enough 
evidence that these tumours originate as odontoamelo-
blastomas and that after being removed they arise again 
as odontoameloblastomas (6,7).
In the new edition (1), calcifying odontogenic tumour 
is once again listed as calcifying odontogenic cyst, be-
cause there is not enough scientific evidence to justify 
considering this entity a neoplasm (6).
In 2005 (4), ameloblastic fibroma could have two vari-
ants depending on which hard dental tissue it presented: 
ameloblastic fibro-dentinoma and ameloblastic fibro-
odontoma. In this new edition (1), it has been decided to 
delete these variants because it was felt that once these 
tumours develop they will turn into odontomas, so in 
the experts’ opinion there was little evidence to justify 
keeping them as separate entities (6,27).
The first 6 cases of primordial odontogenic tumour were 
published in 2014 (13). This tumour is histologically 
composed of variably cellular loose fibrous tissue with 
areas similar to the dental papilla, entirely surrounded 
by cuboidal to columnar epithelium resembling the in-
ternal epithelium of enamel origin.
There have been no major changes to the odontoma 
group in this new edition (1) compared with the previ-
ous one (4).
Ghost cell dentinogenic tumour has been updated as 
well as its immunohistochemistry profile (1).
c) Mesenchymal origin
The previous edition (4) listed two histopathological 
types of odontogenic fibroma: simple and complex. 
This depended on whether the tumour was epithelium 
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poor (simple) or epithelium rich (complex). In this edi-
tion, it was decided to delete this differentiation because 
it was poorly documented (6).
Neither odontogenic myxoma/myxofibroma nor ce-
mentoblastoma have undergone any substantial changes 
in this new edition (1).
Cemento-ossifying fibroma is a neoplasm that was not 
included in the 2005 edition (4) but has been added to 
the 2017 classification (1) under mesenchymal-origin 
odontogenic tumours, in order to distinguish cemento-
ossifying from juvenile forms (trabecular and psam-
momatoid), remarking on its odontogenic origin be-
cause it is believed to arise from periodontal tissue. 
This entity is detailed in the monograph with ossifying 
fibromas in the fibro-osseous and osteochondromatous 
section (1).
Conclusions
The current WHO odontogenic tumours classification 
has been simplified in comparison with the 2005 edition 
with the aim of improving its use as an international guide 
for the diagnosis and management of this pathology.
Many of these changes in classification have been pos-
sible thanks to better genetic and immunohistochem-
istry characterization of some tumours, which was not 
possible in the last edition.
It is important to point out that this classification pro-
cess is far from complete because there are entities such 
as metastasizing ameloblastoma and sclerosing odonto-
genic carcinoma that do not yet have enough scientific 
evidence to be characterized appropriately. In this re-
gard, we would find odontogenic carcinoma with den-
tinoid as well as another evaluation of tumoral entities 
deleted in this classification.
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